<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452540</url>
  </required_header>
  <id_info>
    <org_study_id>DS102A-05-AH1</org_study_id>
    <secondary_id>2018-000819-25</secondary_id>
    <nct_id>NCT03452540</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afimmune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess&#xD;
      the efficacy and safety of orally administered DS102 in patients with acute decompensated&#xD;
      alcoholic hepatitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Company Decision&#xD;
  </why_stopped>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% change in model for end-stage liver disease (MELD) score from baseline</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum bilirubin</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aspartate aminotransferase (AST) levels</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AST:ALT (alanine transaminase) ratio</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Severe Acute Decompensated Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>DS102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive 2000mg DS102 capsules daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will receive placebo capsules daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS102</intervention_name>
    <description>Participants will receive 1000mg DS102 capsules twice per day.</description>
    <arm_group_label>DS102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo capsules twice per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject aged 18 years and older&#xD;
&#xD;
          -  Total bilirubin of ≥ 5 mg/dl (85μmol/l)&#xD;
&#xD;
          -  Patients with definite or probable alcoholic hepatitis (AH)&#xD;
&#xD;
          -  Women of child bearing potential should be willing to practice appropriate&#xD;
             contraception throughout the treatment period&#xD;
&#xD;
          -  Able to swallow the provided study medication&#xD;
&#xD;
          -  Not eligible for liver transplant during this hospitalisation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  History of hypersensitivity to any substance in DS102 capsules or placebo capsules.&#xD;
&#xD;
          -  Duration of clinically apparent jaundice &gt;3 months prior to baseline&#xD;
&#xD;
          -  Other causes of liver disease including:&#xD;
&#xD;
               1. Evidence of chronic viral hepatitis (Hepatitis B DNA positive or Hepatitis C&#xD;
                  (HCV) RNA positive)&#xD;
&#xD;
               2. Biliary obstruction&#xD;
&#xD;
               3. Hepatocellular carcinoma&#xD;
&#xD;
               4. Wilsons disease&#xD;
&#xD;
               5. Budd Chiari Syndrome&#xD;
&#xD;
               6. Non-alcoholic fatty liver disease&#xD;
&#xD;
          -  History of or active non-liver malignancies other than curatively treated skin cancer&#xD;
             (basal cell or squamous cell carcinomas).&#xD;
&#xD;
          -  Treatment with any experimental drug within 30 days prior to Day 0 visit (Baseline),&#xD;
             or 5 half-lives (whichever is longer).&#xD;
&#xD;
          -  Untreated or unresolved sepsis&#xD;
&#xD;
          -  Known infection with HIV at screening or randomization&#xD;
&#xD;
          -  Significant systemic or major illnesses other than liver disease that, in the opinion&#xD;
             of the investigator, would preclude or interfere with treatment with DS102 and/or&#xD;
             adequate follow up.&#xD;
&#xD;
          -  Previous liver transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Hampton Roads</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

